Thomas Woiwode, Director at CRISPR Therapeutics AG (CRSP), bought 227,490 shares at $14.00 ($2.3M) on 2016-10-24, disclosed to the SEC on 2016-12-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 66,490 | $0 | 0.0% |
| 2 | $14.00 | 602 | $8K | 0.4% |
| 3 | $14.00 | 4,583 | $64K | 2.8% |
| 4 | $14.00 | 60,219 | $843K | 37.4% |
| 5 | $14.00 | 95,596 | $1.3M | 59.4% |
| Total | $9.91 avg | 227,490 |
| $2.3M |
| 100% |
| Filing → |
| ALGS | BUY | 2020-10-20 | $3.0M | — | Filing → |
| PASG | BUY | 2020-03-03 | $4.0M | — | Filing → |
| CRSP | SELL | 2018-05-17 | $2.6M | — | Filing → |